医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

眼科医療

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea and Select Southeast Asian Markets for the Treatment of Presbyopia

ヘルスケア眼科医療製薬　 TimeLine: and Zhaoke Ophthalmology Limited Announce Exclusive Licensing Agreement to Commercialize BRIMOCHOL in Greater China Inc.PF and Carbachol PF Visus Therapeutics

2022年05月11日

Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States

ヘルスケア眼科医療製薬　 TimeLine: 1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States Cyclosporine Ophthalmic Emulsion Santen’s Verkazia

2022年05月02日

iHealthScreen Inc. Announces Australian Health (TGA) Approval for iPredictTM Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular degeneration (AMD), and Glaucoma Suspect

ヘルスケア医療機器眼科医療糖尿病　 TimeLine: Age-Related Macular degeneration AMD DR iPredictTM Automated TGA

2022年04月19日

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

LENZ Therapeutics and JIXING Announce an Exclusive Greater China License Agreement; RTW to Invest in LENZ Therapeutics

バイオテクノロジーヘルスケアヘルス一般感染症眼科医療臨床試験製薬　 TimeLine: Announce an Exclusive Greater China License Agreement LENZ Therapeutics and JIXING RTW to Invest in LENZ Therapeutics

2022年04月13日

OPTRACT法 – ドナー角膜や細胞の効率的な輸送技術と無重力環境下での細胞保存による宇宙時代のアンチエイジング研究

OPTRACT法 – ドナー角膜や細胞の効率的な輸送技術と無重力環境下での細胞保存による宇宙時代のアンチエイジング研究

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器眼科医療　 TimeLine: OPTRACT法アンチエイジング研究ドナー角膜細胞輸送技術

2022年03月09日

OPTRACT方法：人类捐献角膜高效运输重大成果；未来太空时代零重力细胞储存库可用于抗衰老研究——日本科学家的战略构想

OPTRACT方法：人类捐献角膜高效运输重大成果；未来太空时代零重力细胞储存库可用于抗衰老研究——日本科学家的战略构想

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器眼科医療　 TimeLine: OPTRACT方法人类捐献角膜高效运输重大成果日本科学家的战略构想未来太空时代零重力细胞储存库可用于抗衰老研究

2022年03月04日

The OPTRACT Method: Efficient Human Donor Cornea Transportation Feat ＆ Futuristic Cell Repository in Zero-gravity for Space-age, Anti-aging Research; Strategy by Japanese Scientists.

The OPTRACT Method: Efficient Human Donor Cornea Transportation Feat ＆ Futuristic Cell Repository in Zero-gravity for Space-age, Anti-aging Research; Strategy by Japanese Scientists.

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器眼科医療　 TimeLine: Anti-aging Research Efficient Human Donor Cornea Transportation Feat Futuristic Cell Repository in Zero-gravity for Space-age Strategy by Japanese Scientists The OPTRACT Method

2022年03月03日

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Clinical Trial Horizon Therapeutics plc Initiates Phase OPTIC-J TED

2022年02月23日

NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China

NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China

ヘルスケア感染症眼科医療製薬　 TimeLine: NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China

2022年02月23日